About Us

Breathing New Life into Proven Medicines

pharmaand GmbH (pharma&) is a privately owned global company headquartered in Vienna, Austria. Since our inception in 2017, we have been dedicated to preserving the availability and fostering the further development of essential medicines worldwide to leave no patient behind. Access to effective medicine is a top priority for healthcare providers and patients. It can be devastating when those medicines are no longer available.

Whether a former blockbuster or niche medicine, we have acquired the worldwide rights to and integrated 10+ high-need specialty therapeutics.

Our global network of partners, combined with our presence in 15 countries with a geographic focus on Europe and the U.S., spans all pharmaceutical functions, making us an integration powerhouse across the development continuum. This includes full value chain capabilities covering the entire product life cycle.

Portfolio of Essential Medicines

As medicines become more mature, they are often given lower priority within a company’s portfolio and eventually may be discontinued. As a commercial-stage company, our global strategy focuses on acquiring worldwide rights to high-need specialty therapeutics, securing long-term access to essential medicines.

pharma& continues to adapt and grow our portfolio across a wide range of therapy areas, with an increasing focus on hematological and oncological treatments. Our portfolio includes essential medicines in the following therapeutic areas:

Acquisition 

pharma&’s early flexibility enables rapid scaling and is part of our strong foundational core. With this agility, we have taken bold steps, such as acquiring Pegasys® (peginterferon alfa-2a) and Rubraca® (rucaparib), to expand our portfolio and capabilities. Our experience allows for fast product and business integration, with an adaptive mindset responsive to business needs and transformation.

This allows for creative business optimization and strategic risk-taking, positioning us to meet our mission long-term: preserving the availability and fostering the further development of essential medicines worldwide to leave no patient behind.

Integrated Organization with Global Reach

With its subsidiaries, joint ventures, and partners, pharma& is a fully integrated organization. This unique approach enables pharma& to provide its portfolio of medicines to eligible patients worldwide by spanning the continuum of research and development, in-house product and active pharmaceutical ingredient (API) manufacturing, distribution via its global partner network, healthcare provider engagement, patient safety services, and patient access services through U.S. Market Access.

• pharma& directly engages with healthcare providers in Europe and the U.S. to promote approved products in approved markets and indications.

• Through partnerships, pharma& distributes its medicines globally.

• pharma&’s joint venture with Summit SD LLC and Heritage Specialty Pharmacy LLC supports the distribution and provision of patient support services within the U.S.

• Loba biotech GmbH, a wholly owned subsidiary of pharma&, produces the API for Pegasys® (peginterferon alfa-2a), helping ensure a stable supply chain and securing future availability for eligible patients.

• pharma& Scheibbs, our secondary packaging facility, ensures packaging efficiency across its portfolio.

Our Exceptional Growth Journey